Lily Wound, a partner in Goodwin’s Technology and Life Sciences groups, has extensive experience representing pharmaceutical, biotechnology, and other life sciences companies in a wide range of complex commercial, corporate, and licensing transactions, including those involving gene therapy, gene editing, engineered cell therapy, and genomic testing. With broad knowledge of licensing and collaboration matters, Ms. Wound has worked on some of the most complex life sciences collaborations in the industry and has handled transactions at every stage of the life cycle of a life sciences product, and has represented early stage to big pharma companies in connection with these transactions. In addition, her roster of domestic and international clients extends to the healthcare, healthcare information and technology, cosmetics, publishing, media, internet, software, and technology industries.
Ms. Wound is also a member of Goodwin’s PropSci practice which is focused on supporting the intersection of Real Estate and Life Sciences through thoughtful collaboration across the two practice areas. As a key contributor to the group and Steering Committee, Ms. Wound stays up to date on relevant market trends impacting the PropSci sector to effectively support clients involved in this space.
Ms. Wound joined Goodwin in 2019 from WilmerHale, where she served as counsel. She has also served as in-house counsel at Hearst Corporation, where she advised on all aspects of Hearst's businesses relating to healthcare information and technology, traditional media, new media, and digital media. Her responsibilities at Hearst included serving as general counsel for an evidence-based medical information and technology company and leading all complex transactions in the newspapers division.
